United Therapeutics Corp (NASDAQ: UTHR) is -8.28% lower on its value in year-to-date trading and has touched a low of $221.53 and a high of $417.82 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The UTHR stock was last observed hovering at around $318.89 in the last trading session, with the day’s gains setting it 4.73%.
Currently trading at $323.62, the stock is -9.07% and -10.33% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.95 million and changing 1.48% at the moment leaves the stock -5.54% off its SMA200. UTHR registered 44.74% gain for a year compared to 6-month gain of -6.65%.
The stock witnessed a -12.74% loss in the last 1 month and extending the period to 3 months gives it a -13.21%, and is -11.91% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.10% over the week and 3.64% over the month.
United Therapeutics Corp (UTHR) has around 1305 employees, a market worth around $14.45B and $2.88B in sales. Current P/E ratio is 13.16 and Fwd P/E is 11.17. Profit margin for the company is 41.53%. Distance from 52-week low is 46.08% and -22.54% from its 52-week high. The company has generated returns on investments over the last 12 months (18.55%).
with sales reaching $736.27M over the same period.The EPS is expected to grow by 15.14% this year, but quarterly earnings will post 9.07% year-over-year. Quarterly sales are estimated to grow 8.64% in year-over-year returns.
The shares outstanding are 44.83M, and float is at 43.80M with Short Float at 4.72%.
The top institutional shareholder in the company is BLACKROCK INC. with over 5.47 million shares valued at $1.74 billion. The investor’s holdings represent 11.6362 of the UTHR Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 4.42 million shares valued at $1.41 billion to account for 9.402 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 3.29 million shares representing 6.99 and valued at over $1.05 billion, while AVORO CAPITAL ADVISORS LLC holds 6.4389 of the shares totaling 2.86 million with a market value of $910.7 million.
United Therapeutics Corp (UTHR) Insider Activity
The most recent transaction is an insider sale by BENKOWITZ MICHAEL, the company’s PRESIDENT AND COO. SEC filings show that BENKOWITZ MICHAEL sold 10,000 shares of the company’s common stock on Feb 24 ’25 at a price of $360.76 per share for a total of $3.61 million. Following the sale, the insider now owns 0.0 shares.
United Therapeutics Corp disclosed in a document filed with the SEC on Feb 18 ’25 that BENKOWITZ MICHAEL (PRESIDENT AND COO) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Feb 18 ’25 and was made at $371.05 per share for $3.71 million. Following the transaction, the insider now directly holds 0.0 shares of the UTHR stock.
Still, SEC filings show that on Feb 10 ’25, BENKOWITZ MICHAEL (PRESIDENT AND COO) disposed off 10,000 shares at an average price of $348.06 for $3.48 million. The insider now directly holds 0 shares of United Therapeutics Corp (UTHR).
